AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-21. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
=== Regulation === In some jurisdictions, the sale or possession of hypodermic syringes may be controlled or prohibited without a prescription, due to its potential use with illegal intravenous drugs.
=== Actin/myosin movement === In addition to the physical force generated by actin polymerization, microfilaments facilitate the movement of various intracellular components by serving as the roadway along which a family of motor proteins called myosins travel.
=== ThermoFluor of membrane proteins === Membrane proteins are often isolated in the presence of hydrophobic solubilizing agents that can partition hydrophobic-binding dyes like 1,8-ANS and SYPRO orange and generate a fluorescence background that obscures observation of a Thermofluor protein melting signal. Nevertheless, careful optimization of conditions (e.g., to avoid micelle formation of the solubilizing agent) can often produce satisfactory assay conditions
=== Ion source === Ion sources are fundamental to ion milling. Their design and operation are crucial to producing accurate results. The most commonly used ion source relies on radiofrequency (RF) ion sources and direct current (DC) electric fields to generate and accelerate ions from a gas, typically a noble gas like argon or xenon. RF fields are used for ionization because they allow for a high degree of control and efficiency. RF ion sources can efficiently produce ions by creating an alternating radiofrequency electric field in a resonant cavity. RF uses a frequency of several megahertz, which works best for most gases used. The RF field causes the gas to repeat cycles of ionization and electron detachment, which creates plasma. The alternating electric field ionizes the gas by ripping off the electrons and leaving the positive ions. The ions are then accelerated away from the plasma using a DC electric field. An extraction electrode with a DC electric field accelerates the ions towards the specimen due to the voltage difference between the electrode and plasma region. The synergy between RF and DC fields is crucial for optimizing the ion source's performance. The precise combination between these fields gives the ion beam the specific characteristics it needs, such as energy and current.
Owing to variations in humidity and (likely) clothing, recommendations for summer and winter may vary; a suggested typical range for summer is 23–25.5 °C (73–78 °F), with that for winter being 20–23.5 °C (68–74 °F). Some studies have suggested that thermal comfort preferences of men and women may differ significantly, with women on average preferring higher ambient temperatures. Rooms may be maintained at an ambient temperature above the comfort temperature in hot weather, or below it in cold weather, if required by cost considerations or practical issues (e.g. lack of air conditioning or relatively high expense of heating). In the recent past, it was common for winter house temperatures to be kept below the comfort level; a 1978 UK study found average indoor home temperatures to be 15.8 °C (60.4 °F) while Japan in 1980 had median home temperatures of 13 °C (55 °F) to 15 °C (59 °F).
Sources: en.wikipedia.org
=== Research === A major source of bubble instability is when a wide variety of sizes of bubbles are created, gases in smaller bubbles diffuses or disperses into larger bubbles. This is due to their differing Laplace pressures. As of 2023, technologies to control bubble size, distribution and movement were difficult to employ during production. "Advanced" research was underway, including by companies such as Nestlé. In 2013, scientists released the results of experimental research on the impact of phospholipids on aerating cocoa butter. The research found that although all phospholipids tested made cocoa butter foam more, the foam's stability varied by type of phospholipid. The final cocoa butter was also observed to be more stable when the process was undertaken at lower temperatures.
At the time of the Miller–Urey experiment, Harold Urey was a Professor of Chemistry at the University of Chicago who had a well-renowned career, including receiving the Nobel Prize in Chemistry in 1934 for his isolation of deuterium and leading efforts to use gaseous diffusion for uranium isotope enrichment in support of the Manhattan Project. In 1952, Urey postulated that the high temperatures and energies associated with large impacts in Earth's early history would have provided an atmosphere of methane (CH4), water (H2O), ammonia (NH3), and hydrogen (H2), creating the reducing environment necessary for the Oparin-Haldane "primordial soup" scenario. Stanley Miller arrived at the University of Chicago in 1951 to pursue a PhD under nuclear physicist Edward Teller, another prominent figure in the Manhattan Project. Miller began to work on how different chemical elements were formed in the early universe, but, after a year of minimal progress, Teller was to leave for California to establish Lawrence Livermore National Laboratory and further nuclear weapons research. Miller, having seen Urey lecture on his 1952 paper, approached him about the possibility of a prebiotic synthesis experiment. While Urey initially discouraged Miller, he agreed to allow Miller to try for a year. By February 1953, Miller had mailed a manuscript as sole author reporting the results of his experiment to Science.
== Reception == The museum has consistently received favorable press. The Kansas City Star named it "Rookie of the Year" in 1992 after having received over 20,000 visitors in two months. As of 2013, it continued to draw more than 80,000 visitors per year. It is described by the Wall Street Journal as "fascinating" museum with an "enthralling" story. US News & World Report ranks it number one on its list of "Best Things To Do in Kansas City". After remodeling the ceiling and displays in January 2013, the museum was awarded "Best Remodel" by local weekly publication The Pitch.
Muscle cells work by detecting a flow of electrical impulses from the brain which signals them to contract through the release of calcium by the sarcoplasmic reticulum. Fatigue (reduced ability to generate force) may occur due to the nerve, or within the muscle cells themselves.
Mahathir bin Mohamad (Jawi: محاضر بن محمد; Malay: [mahade(r) muhammad, -ðe(r)] ; born 10 July 1925) is a Malaysian politician, physician and author who served as the fourth and seventh prime minister of Malaysia from 1981 to 2003 and again from 2018 to 2020. He was the country's longest-serving prime minister, serving for a cumulative total of 24 years. His political career has spanned more than 75 years, from joining protests opposing citizenship policies for non-Malays in the Malayan Union in the 1940s to forming the Gerakan Tanah Air coalition in 2022. During his premiership, Mahathir was granted the title "Father of Modernisation" (Malay: Bapa Pemodenan) for his pivotal role in transforming the country's economy and infrastructure. At 101 years old, he is the second-oldest living former state leader in the world and the first Malaysian prime minister to reach that age. Born and raised in Alor Setar, Kedah, Mahathir excelled at school and became a physician. He became active in UMNO before entering the parliament of Malaysia in 1964 as the Member of Parliament for Kota Setar Selatan, serving until he lost his seat in 1969, subsequently falling out with Prime Minister Tunku Abdul Rahman and being expelled from UMNO. In 1970, he released the book The Malay Dilemma. When Tunku resigned, Mahathir re-entered UMNO and parliament through Kubang Pasu constituency, and was promoted to Minister of Education from 1974 to 1978 and Minister of Trade and Industry from 1978 to 1981. He became deputy prime minister in 1976 before being sworn in as prime minister in 1981.
Sources: en.wikipedia.org
=== Etymology and pronunciation === The name "Liliaceae" (English: ) comes to international scientific vocabulary from Neo-Latin, from Lilium, the type genus, + -aceae, a standardized suffix for plant family names in modern taxonomy. The genus name comes from the Classical Latin word lilium, "lily", which in turn came from the Greek leírion (λείριον). Because of the history of Liliaceae, many species such as Watsonia (bugle lily) that were previously classified in this family bear the name 'lily' but are neither part of the genus Lilium, or the family Liliaceae.
frameshift mutation A type of mutation in a nucleic acid sequence caused by the insertion or deletion of a number of nucleotides that is not divisible by three. Because of the triplet nature by which nucleotides code for amino acids, a mutation of this sort causes a shift in the reading frame of the nucleotide sequence, resulting in the sequence of codons downstream of the mutation site being completely different from the original.
== Regulatory harmonization == In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and the European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
=== Diabetic foot ulcers === A 2024 meta-analysis reported that the growth factors present in PRP are vital in the healing of diabetic foot ulcers; specifically in their closure. The treatments were reported to significantly increase the healing rate in comparison to conventional treatments.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.